APO010, A synthetic hexameric CD95 ligand, induces death of human glioblastoma stem-like cells

Anticancer Research

Volumn 33, Issue 9, 2013, Pages 3563-3572

  Eisele, Günter ^a   Wolpert, Fabian ^a   Decrey, Guillaume ^a   Weller, Michael ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Apoptosis; CD95 ligand; Glioma stem cell; Temozolomide

Indexed keywords

ANTINEOPLASTIC AGENT; APO 010; FAS LIGAND; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER STEM CELL; CELL DEATH; CELL DIFFERENTIATION; CELL POPULATION; CELL SURFACE; CONTROLLED STUDY; FLOW CYTOMETRY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL CULTURE;

APOPTOSIS; CD95 LIGAND; GLIOMA STEM CELL; TEMOZOLOMIDE;

ANTIGENS, CD; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; CELL LINE, TUMOR; DACARBAZINE; FAS LIGAND PROTEIN; GLIOBLASTOMA; GLYCOPROTEINS; HUMANS; NEOPLASTIC STEM CELLS; PEPTIDES; RECOMBINANT FUSION PROTEINS;

EID: 84884992703     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Johnson DR, Ma DJ, Buckner JC and Hammack JE: Conditional probability of long-term survival in glioblastoma: a populationbased analysis. Cancer 118: 5608-5613, 2012.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E and Mirimanoff RO: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
3. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB: Identification of human brain tumour initiating cells. Nature 432: 396-401, 2004.
4. Tabatabai G and Weller M: Glioblastoma stem cells. Cell Tissue Res 343: 459-465, 2011.
5. Cheng L, Bao S and Rich JN: Potential therapeutic implications of cancer stem cells in glioblastoma. Biochem Pharmacol 80: 654-665, 2010.
6. Tamura K, Aoyagi M, Wakimoto H, Ando N, Nariai T, Yamamoto M and Ohno K: Accumulation of CD133-positive glioma cells after high-dose irradiation by Gamma Knife surgery plus external beam radiation. J Neurosurg 113: 310-318, 2010.
7. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760, 2006.
8. Gunther HS, Schmidt NO, Phillips HS, Kemming D, Kharbanda S, Soriano R, Modrusan Z, Meissner H, Westphal M and Lamszus K: Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene 27: 2897-2909, 2008.
9. Beier CP and Beier D: CD133 negative cancer stem cells in glioblastoma. Front Biosci 3: 701-710, 2011.
10. Bar EE, Lin A, Mahairaki V, Matsui W and Eberhart CG: Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. Am J Pathol 177: 1491-1502, 2010.
11. Eisele G and Weller M: Targeting apoptosis pathways in glioblastoma. Cancer Lett 332: 335-345, 2013.
12. Weller M, Frei K, Groscurth P, Krammer PH, Yonekawa Y and Fontana A: Anti-FAS/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. J Clin Invest 94: 954-964, 1994.
13. Weller M, Malipiero U, Rensing-Ehl A, Barr PJ and Fontana A: FAS/APO-1 gene transfer for human malignant glioma. Cancer Res 55: 2936-2944, 1995.
14. Roth W, Fontana A, Trepel M, Reed JC, Dichgans J and Weller M: Immunochemotherapy of malignant glioma: synergistic activity of CD95 ligand and chemotherapeutics. Cancer Immunol Immunother 44: 55-63, 1997.
15. Holler N, Tardivel A, Kovacsovics-Bankowski M, Hertig S, Gaide O, Martinon F, Tinel A, Deperthes D, Calderara S, Schulthess T, Engel J, Schneider P and Tschopp J: Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a deathinducing signaling complex. Mol Cell Biol 23: 1428-1440, 2003.
16. Eisele G, Roth P, Hasenbach K, Aulwurm S, Wolpert F, Tabatabai G, Wick W and Weller M: APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo. Neuro Oncol 13: 155-164, 2011.
17. Schulte A, Gunther HS, Martens T, Zapf S, Riethdorf S, Wulfing C, Stoupiec M, Westphal M and Lamszus K: Glioblastoma stemlike cell lines with either maintenance or loss of high-level EGFR amplification, generated via modulation of ligand concentration. Clin Cancer Res 18: 1901-1913, 2012.
18. Schulte A, Gunther HS, Phillips HS, Kemming D, Martens T, Kharbanda S, Soriano RH, Modrusan Z, Zapf S, Westphal M and Lamszus K: A distinct subset of glioma cell lines with stem celllike properties reflects the transcriptional phenotype of glioblastomas and overexpresses CXCR4 as therapeutic target. Glia 59: 590-602, 2011.
19. Wolpert F, Roth P, Lamszus K, Tabatabai G, Weller M and Eisele G: HLA-E contributes to an immune-inhibitory phenotype of glioblastoma stem-like cells. J Neuroimmunol 250: 27-34, 2012.
20. Webb J: Effects of more than one inhibitor. In: Enzymes and Metabolic Inhibitors (Webb J (ed.). New York: Academic Press, pp. 487-512, 1963.
21. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan Z, Feuerstein BG and Aldape K: Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9: 157-173, 2006.
22. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM and Hayes DN: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110, 2010.
23. Johnson DE, Gastman BR, Wieckowski E, Wang GQ, Amoscato A, Delach SM and Rabinowich H: Inhibitor of apoptosis protein hILP undergoes caspase-mediated cleavage during T lymphocyte apoptosis. Cancer Res 60: 1818-1823, 2000.
24. Kleber S, Sancho-Martinez I, Wiestler B, Beisel A, Gieffers C, Hill O, Thiemann M, Mueller W, Sykora J, Kuhn A, Schreglmann N, Letellier E, Zuliani C, Klussmann S, Teodorczyk M, Grone HJ, Ganten TM, Sultmann H, Tuttenberg J, von Deimling A, Regnier-Vigouroux A, Herold-Mende C and Martin-Villalba A: YES and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 13: 235-248, 2008.
25. Rieger J, Frank B, Weller M and Wick W: Mechanisms of resistance of human glioma cells to APO2 ligand/TNF-related apoptosis-inducing ligand. Cell Physiol Biochem 20: 23-34, 2007.
26. Wick W, Weller M, Weiler M, Batchelor T, Yung AW and Platten M: Pathway inhibition: Emerging molecular targets for treating glioblastoma. Neuro Oncol 13: 566-579, 2011.
27. Bertrand J, Begaud-Grimaud G, Bessette B, Verdier M, Battu S and Jauberteau MO: Cancer stem cells from human glioma cell line are resistant to Fas-induced apoptosis. Int J Oncol 34: 717-727, 2009.
28. Etter AL, Bassi I, Germain S, Delaloye JF, Tschopp J, Sordat B and Dupuis M: The combination of chemotherapy and intraperitoneal megaFAS ligand improves treatment of ovarian carcinoma. Gynecol Oncol 107: 14-21, 2007.
29. Rikhof B, van der Graaf WT, Meijer C, Le PT, Meersma GJ, de Jong S, Fletcher JA and Suurmeijer AJ: Abundant FAS expression by gastrointestinal stromal tumours may serve as a therapeutic target for megaFASL. Br J Cancer 99: 1600-1606, 2008.